ПРИМЕНЕНИЕ СИЛОДОЗИНА ДЛЯ ЛЕЧЕНИЯ БОЛЬНЫХ АДЕНОМОЙ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ


Цитировать

Полный текст

Открытый доступ Открытый доступ
Доступ закрыт Доступ предоставлен
Доступ закрыт Доступ платный или только для подписчиков

Аннотация

Полный текст

Доступ закрыт

Об авторах

А. В. Говоров

ГБОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития России

Email: alexgovorov@newmail.ru
канд. мед. наук, доц. каф. урологии

Д. Ю. Пушкарь

ГБОУ ВПО Московский государственный медико-стоматологический университет Минздравсоцразвития России

Кафедра урологии

Список литературы

  1. McVary K. T., Roehrborn C. G., Avins A. L. et al. Update on AUA Guideline on he management of benign prostatic hyperplasia. J. Urol. (Baltimore) 2011; 185: 1793—1803.
  2. Curran M. P. Silodosin. Treatment of the signs and symptoms of benign prostatic hyperplasia. Drugs 2011; 71: 897—907.
  3. Shibata K., Foglar R., Horie K. et al. KMD-3213, a novel, potent a1A-adrenoceptor-selective antagonist: characterization using recombinant human a1A-adrenoceptors and native tissues. Mol. Pharmacol. 1995; 48: 250—258.
  4. Tatemishi S., Kobayashi K., Maezawa A. et al. a1A-Adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi 2006; 126: 209—216.
  5. Tatemishi S., Kiguchi S., Kobayashi M. et al. Cardiovascular effects of the selective a1A-adrenoceptor antagonist silodosin (KMD-3213), a drug for the treatment of voiding dysfunction. Arzneimittel-Forschung 2006; 56: 682—687.
  6. Morganroth J., Lepor H., Hill L. A. et al. Effects of the selective a1A-adrenoceptor antagonist silodosin on ECGs of healthy men in a randomized, double-blind, placebo- and moxifloxacin-controllled study Clin. Pharmacol. Ther. 2010; 87: 609—613.
  7. EPARs for authorized medicinal products for human use: Urorec. European Medicines Agency Web site. http://www.ema.europa.eu/humandocs/Humans/EPAR/urorec.htm.
  8. Lepor H., Hill L. A. Silodosin for the treatment of benign prostatic hyperplasia: pharmacology and cardiovascular tolerability. Pharmacotherapy 2010; 30: 1303—1312.
  9. Strittmatter F., Hedlund P. Silodosin — from preclinical development to clinical trials. Aging Health 2011; 7: 45—57.
  10. Okura T., Yamada S., Abe Y. et al. Selective and sustained occupancy of prostatic a1-adrenoceptors by oral administration of KMD-3213 and its plasma concentration in rats. J. Pharm. Pharmacol. 2002; 54: 975—982.
  11. Akiyama K., Tatemichi S., Katayama S. et al. Relationship between prostatic a1-adrenoceptor binding and reduction in intraurethral pressure following continuous infusion of KMD-3213 in rats. Pharmacology 2002; 64: 140—147.
  12. Kawabe K., Yoshida M., Homma Y. Silodosin, a new alA-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebocontrolled, double-blind study in Japanese men. Br. J. Urol. Int. 2006; 98: 1019—1024.
  13. Van DijkM. M., de la Rosette J. J. M. C. H., Michel M. C. Effects of a1A-adrenoceptor antagonists on male sexual function. Drugs 2006; 66: 287—301.
  14. Nagai A., Hara R., Yokoyama T. et al. Ejaculatory dysfunction caused by the new a1A-blocker silodosin: a preliminary study to analyze human ejaculation using color Doppler ultrasonography. Int. J. Urol. 2008; 15: 915—918.
  15. Yono M., Yamamoto Y., Imanishi A. et al. Short and long-term effects of silodosin, a selective a1A-adrenoceptor antagonist, on ejaculatory function in rats. Br. J. Urol. Int. 2009; 103: 1680—1685.
  16. Roehroborn C. G., Lepor H., Kaplan S. A. Retrograde ejaculation induced by silodosin is the result of relaxation of smooth musculature in the male uro-genital tracts and is associated with greater urodynamic and symptomatic improvements in men LUTS secondary to BPH (abstract). J. Urol. (Baltimore) 2009; 181 (Suppl.): 694.
  17. Yukio H., Kazuki K., Masayuki T. et al. Ejaculation disorder is associated with increased efficacy of silodosin for benign prostatic hyperplasia. Urology 2010; 76: 1446—1450.
  18. Avisar R., Weinberger D. Intraoperative floppy iris syndrome: possible relationship with alpha-1 adrenergic receptor antagonists. Isr. Med. Assocl. J. 2009; 11: 43—44.
  19. Marks L. S., Gittelman M. C., Hill L. A. et al. Rapid efficacy of the highly selective alpha1A-adrenoceptor antagonist silodosin in men with signs and symptoms of benign prostatic hyperplasia: pooled results of 2 phase 3 studies. J. Urol. (Baltimore) 2009; 181: 2634—2640.
  20. Marks L. S., Gittelman M. C., Hill L. A. et al. Silodosin in the treatment of the signs and symptoms of benign prostatic hyperplasia: a 9-month, open-label extension study. Urology 2009; 74: 1318—1322.
  21. Michel M. C. The pharmacological profile of the a1A-adrenoceptor antagonist silodosin. Eur. Urol. Suppl. 2010; 9: 486—490.
  22. Kobayashi S., Tomiyama Y., Tatemichi S. et al. Effects of silodosin and tamsulosin on the urethra and cardiovascular system in young and old dogs with benign prostatic hyperplasia. Eur. J. Pharmacol. 2009; 613: 135—140.
  23. MacDiarmid S. A., Hill L. A., Volinn W. et al. Lack of pharmacodynamic interaction of silodosin, a highly selective alpha a1A-adrenoceptor antagonist, with the phosphodiesterase-5 inhibitors sildenafil and tadalafil in healthy men. Urology 2010; 75: 520—525.
  24. Chapple C. R., Montorsi F., Tammela T. et al. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur. Urol. 2011; 59: 342—352.
  25. Morgia G. Does the use of silodosin to treat benign prostatic hyperplasia really offer something new? Eur. Urol. 2011; 59: 353—355.
  26. Yu H. J., Lin A. T., Yang S. S. et al. Non-inferiority of silodosin to tamsulosin in treating patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Br. J. Urol. Int. 2011; 108 (11): 1843—1848.
  27. Matsukawa Y., Hattori R., Yanamoto T. et al. Long-term efficacy of silodosin on the lower urinary tract function in patients with benign prostatic hyperplasia according to prostate size: prospective investigation using pressure-flow study. Eur. Urol. Suppl. 2011; 10 (2): 121, abstr. 330.
  28. Michel M. C., Casi M., Anonellini A. Silodosin consistently improves nocturia in men with LUTS suggestive of BPH. Analysis of three phase III placebo-controlled studies. Eur. Urol. Suppl. 2011; 10 (2): 121—122, anstr. 331.
  29. Nickel J. C., O’Leary M. P., Lepor H. et al. Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J. Urol. (Baltimore) 2011; 186: 125—131.
  30. Russo A., Hedlund P., Montorsi F. Silodosin from bench to bedside: selectivity, safety, and sustained efficacy. Eur. Urol. Suppl. 2011; 10: 445—450.
  31. Yoshida M., Kudoh J., Homma Y. et al. Safety and efficacy of silodosin for the treatment of benign prostatic hyperplasia. Clin. Interv. Aging 2011; 6: 161—172.
  32. Montorsi F. Profile of silodosin. Eur. Urol. Suppl. 2010; 9: 491—495.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© ООО «Бионика Медиа», 2012

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах